Compare Summit Therapeutics Inc (SMMT) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Seagate Technology Holdings PLC — how do they compare? Summit Therapeutics Inc trades at $17.44 (market cap $13.71B), while Seagate Technology Holdings PLC trades at $783.28 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 12.9× Summit Therapeutics Inc's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Seagate Technology Holdings PLC for 41 Days on average.
| SMMT | STX | |
|---|---|---|
Market Cap | $13.71B | $176.19B |
Volume | 6,173,057 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $26.38 | $1.09K |
52-Week Low | $12.43 | $211.63 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $13.04B | $178.34B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Seagate Technology (STX) trades at $780.39, down 3.34% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamental performance with Q2 2026 EPS beating expectations at $5.71 versus $5.10, and maintains robust profitability with 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price below key pivot points, though RSI suggests potential oversold conditions at 24.89.
Despite near-term competitive pressures, Seagate's dominant position in AI storage and strong earnings trajectory support long-term growth. The consensus price target of $1,130 represents 45% upside potential, but investors face risks from pricing pressure and market share erosion as Toshiba expands capacity in 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
